17,261 trials
Bacterial Vaginosis · Candidiasis · Trichomoniasis
Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…
Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IV Non-small Cell Lung Cancer
Primary: Progression Free Survival — 3.4; 4.2; 4.0 months
Hepatitis C
Primary: Participants With Adverse Events — 1; 1; 5; 0 partipants
Healthy
Primary: Number of Participants With Solicited Symptoms After Dose 1 — 65; 68; 61; 59 participants
Mild Cognitive Impairment · Alzheimer's Disease
Primary: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) — 49; 81; 106; 32.5 units on a scale
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Japanese Encephalitis · Hepatitis A
Primary: Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection — 15; 13; NA; NA…
Ovarian Cancer
Primary: Phase I: Maximum Tolerated Dose (MTD) for Use in Phase II — 10 mg/m2 IV QD x 5 days
Graft Versus Host Disease
Primary: Percentage of Patients Alive at 6 Months — 83 percentage of patients
Rhinitis, Allergic, Perennial and Seasonal
Primary: Weighted Mean of the Total Nasal Symptom Score (TNSS) (0-4) Hours (h) Post Start of Allergen Chamber Challenge on Day 8 — 5.190; 4.071; 3.840 Scores on a scale — p=<0.0001
Constipation
Primary: Number of Participants With Inflammation of the Oral Mucosa — 31; 34; 0; 0 Particpants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Dichotomized Baseline Plasma Marker Level — 42.86; 47.69…
Moderate Depression · Menopausal and Postmenopausal Disorders
Primary: Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks. — 9.9; 11.7; 15 Units in Hamilton Scale — p=<0.05
Gynecologic Cancer · Post-operative Pain
Primary: 24 Hour Post Operative Opioid Consumption, Converted to Intravenous Morphine Equivalents — 64.9; 69.3 mg
Estrogen Receptor-negative Breast Cancer · Progesterone Receptor-negative Breast Cancer · Recurrent Breast Cancer
Primary: Clinical Benefit Rate (CR + PR + SD > 6 Months). — 7.1; 6.3 Percent of Participants